HLS Therapeutics Inc
HLS
Company Profile
Business description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
Contact
10 Carlson Court
Suite 701
Etobicoke
TorontoONM9W 6L2
CANT: +1 647 495-9000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
86
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
stocks
Alphabet returns on AI investments accelerating
AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,887.60 | 17.10 | 0.19% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,652.14 | 790.33 | 1.62% |
| FTSE 100 | 10,378.82 | 165.71 | 1.62% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 24,892.31 | 219.07 | 0.89% |
| Nikkei 225 | 59,284.92 | 632.54 | -1.06% |
| NZX 50 Index | 12,892.97 | 10.34 | -0.08% |
| S&P 500 | 7,209.01 | 73.06 | 1.02% |
| S&P/ASX 200 | 8,665.80 | 25.60 | 0.30% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |